All companies › DNTH

DNTH · Dianthus Therapeutics, Inc. /DE/

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research case for this company.

Open-market buys0
Open-market sells9
Research cases0
Last filing2026-09-17

Insider flow: Selling only — a count of disclosed transactions, not a rating or a recommendation.

Insider transaction timeline

Every reported transaction, positioned by trade date. Purchases sit above the axis, sales below; circle area is proportional to dollar value. No share-price line is drawn — this feed carries transaction prices only, and a price history inferred from them would imply market data the filings do not contain.

Open-market purchase Open-market sale
2026-08-19 — Read Simon · sold 2,778 @ $117.55 2026-09-01 — Randhawa Simrat · sold 13,309 @ $106.74 2026-09-01 — Randhawa Simrat · sold 2,600 @ $105.19 2026-09-01 — Randhawa Simrat · sold 7,215 @ $106.25 2026-09-17 — CARR EDWARD · sold 1,100 @ $103.20 2026-09-17 — CARR EDWARD · sold 3,501 @ $102.39 2026-09-17 — CARR EDWARD · sold 6,771 @ $101.37 2026-09-17 — CARR EDWARD · sold 700 @ $104.39 2026-09-17 — CARR EDWARD · sold 7,928 @ $100.43
2026-08-192026-09-17

Insider participation

One row per insider, one cell per reported transaction, shaded by value. Repeat buying and activity clustered in time are visible at a glance.

CARR EDWARD CHIEF ACCOUNTING OFFICER
Randhawa Simrat EVP, Head of R&D
Read Simon Director
Included with a free account

The analysis built on top of these filings

The filings above are public record and stay public here. What an account adds for $DNTH is the reading of them — and for this company, that is what the list below says it is, no more.

  • Transaction timelineThe [{'transaction_date': '2026-09-17', 'insider_name': 'CARR EDWARD', 'insider_title': 'CHIEF ACCOUNTING OFFICER', 'transaction_type': 'Open-market sell', 'shares': 1100.0, 'price': 103.2, 'value': 113520.0, 'is_buy': False}, {'transaction_date': '2026-09-17', 'insider_name': 'CARR EDWARD', 'insider_title': 'CHIEF ACCOUNTING OFFICER', 'transaction_type': 'Open-market sell', 'shares': 3501.0, 'price': 102.39, 'value': 358467.39, 'is_buy': False}, {'transaction_date': '2026-09-17', 'insider_name': 'CARR EDWARD', 'insider_title': 'CHIEF ACCOUNTING OFFICER', 'transaction_type': 'Open-market sell', 'shares': 6771.0, 'price': 101.37, 'value': 686376.27, 'is_buy': False}, {'transaction_date': '2026-09-17', 'insider_name': 'CARR EDWARD', 'insider_title': 'CHIEF ACCOUNTING OFFICER', 'transaction_type': 'Open-market sell', 'shares': 700.0, 'price': 104.39, 'value': 73073.0, 'is_buy': False}, {'transaction_date': '2026-09-17', 'insider_name': 'CARR EDWARD', 'insider_title': 'CHIEF ACCOUNTING OFFICER', 'transaction_type': 'Open-market sell', 'shares': 7928.0, 'price': 100.43, 'value': 796209.04, 'is_buy': False}, {'transaction_date': '2026-09-01', 'insider_name': 'Randhawa Simrat', 'insider_title': 'EVP, Head of R&D', 'transaction_type': 'Open-market sell', 'shares': 13309.0, 'price': 106.74, 'value': 1420602.66, 'is_buy': False}, {'transaction_date': '2026-09-01', 'insider_name': 'Randhawa Simrat', 'insider_title': 'EVP, Head of R&D', 'transaction_type': 'Open-market sell', 'shares': 2600.0, 'price': 105.19, 'value': 273494.0, 'is_buy': False}, {'transaction_date': '2026-09-01', 'insider_name': 'Randhawa Simrat', 'insider_title': 'EVP, Head of R&D', 'transaction_type': 'Open-market sell', 'shares': 7215.0, 'price': 106.25, 'value': 766593.75, 'is_buy': False}, {'transaction_date': '2026-08-19', 'insider_name': 'Read Simon', 'insider_title': 'Director', 'transaction_type': 'Open-market sell', 'shares': 2778.0, 'price': 117.55, 'value': 326553.9, 'is_buy': False}] reported transactions plotted over the window rather than listed, so concentration is visible.

Not available for DNTH today: no reported open-market purchases in this window, so there is no insider cost basis to compute; no research case — nothing here has cleared the scoring threshold. Both appear on this page on their own if that changes.

A free account opens all of it.

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.